GB3

24 Hours of Le Mans Virtual Continues to Attract Champions From Around the World for Final Round of 2022-23 Season

Retrieved on: 
Thursday, January 5, 2023

MIAMI, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or the “Company”) today announced another star-studded entry list has been released for the third edition of the 24 Hours of Le Mans Virtual, the final round of the 2022-23 Le Mans Virtual Series season. The event will take place on January 14 & 15, 2023 and will be held virtually, with the 180 drivers on simulators located all around the world.

Key Points: 
  • MIAMI, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or the “Company”) today announced another star-studded entry list has been released for the third edition of the 24 Hours of Le Mans Virtual, the final round of the 2022-23 Le Mans Virtual Series season.
  • The event will take place on January 14 & 15, 2023 and will be held virtually, with the 180 drivers on simulators located all around the world.
  • The award-winning virtual event continues to be a huge draw for drivers at the top of their game in both the real and sim racing worlds.
  • Further details will be revealed in the coming days about individual car liveries, plus how you can follow the 24 Hours of Le Mans Virtual on television, online and on social media channels around the world.

Fabry Disease Market to Boost at a CAGR of 7.65% by 2032 | DelveInsight

Retrieved on: 
Tuesday, October 4, 2022

DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
  • The increasing prevalence of the disease, along with the promising emerging pipeline therapies with new mechanisms of action, will fuel the Fabry disease market during the forecast period.
  • In the European and Japanese Fabry disease treatment market, Replagal (Takeda/Shire), Fabrazyme (Sanofi-Genzyme), and Galafold (Amicus Therapeutics) are currently the only approved therapies for Fabry disease patients.
  • To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market

Fabry Disease Market to Boost at a CAGR of 7.65% by 2032 | DelveInsight

Retrieved on: 
Tuesday, October 4, 2022

DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • DelveInsight's Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].
  • The increasing prevalence of the disease, along with the promising emerging pipeline therapies with new mechanisms of action, will fuel the Fabry disease market during the forecast period.
  • In the European and Japanese Fabry disease treatment market, Replagal (Takeda/Shire), Fabrazyme (Sanofi-Genzyme), and Galafold (Amicus Therapeutics) are currently the only approved therapies for Fabry disease patients.
  • To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market

uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)

Retrieved on: 
Tuesday, October 19, 2021

and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.

Key Points: 
  • and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that four data presentations, including one oral presentation, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) 28th Annual Meeting taking place virtually today through October 22, 2021.
  • AMT-191 is a one-time administered AAV5 gene therapy incorporating an -galactosidase A (GLA) transgene.
  • Moreover, pre-clinical studies in non-human primates with AMT-191 demonstrated robust and sustained increases in GLA activity in multiple organs.
  • uniQure is delivering on the promise of gene therapy single treatments with potentially curative results.